Böhm, M., Young, R., Jhund, P. S., Solomon, S. D., Gong, J., Lefkowitz, M. P., … McMurray, J. J. V. (2017). Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal, 38(15), 1132–1143. https://doi.org/10.1093/eurheartj/ehw570

Böhm, Michael, Robin Young, Pardeep S. Jhund, Scott D. Solomon, Jianjian Gong, Martin P. Lefkowitz, Adel R. Rizkala, et al. “Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.” European Heart Journal 38, no. 15 (April 14, 2017): 1132–43. https://doi.org/10.1093/eurheartj/ehw570.

Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, et al. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal. 2017 Apr 14;38(15):1132–43.

Böhm, Michael, et al. “Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.” European Heart Journal, vol. 38, no. 15, Oxford University Press (OUP), Apr. 2017, pp. 1132–43. Crossref, doi:10.1093/eurheartj/ehw570.

Böhm M, Young R, Jhund PS, Solomon SD, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K, Zile MR, Packer M, McMurray JJV. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. European Heart Journal. Oxford University Press (OUP); 2017 Apr 14;38(15):1132–1143.